This study is NOT currently recruiting participants.
Number
14-HG-0125
Sponsoring Institute
National Human Genome Research Institute (NHGRI)
Recruitment Detail
Type: Completed Study; data analyses ongoing Gender: Male & Female Min Age: 18 Years Max Age: 120 Years
Referral Letter Required
No
Population Exclusion(s)
Children
Keywords
Genetic Disorders; Health contributors; Multifactorial; African American; African; Natural History
Recruitment Keyword(s)
None
Condition(s)
Genetic Disease; Genomics
Investigational Drug(s)
Investigational Device(s)
Intervention(s)
Supporting Site
National Human Genome Research Institute
- People with sickle cell disease and other blood disorders sometimes get chronic leg ulcers. These are wounds that develop on the skin and don t go away. Current treatments do not work very well, so researchers want to learn more about why the ulcers happen. They want to find out which bacteria may cause it, and if external factors play a role.
Objective:
- To study social and environmental factors of sickle cell disease and the causes of sickle cell disease leg ulcers.
Eligibility:
- People age 18 and older who have sickle cell disease or another red cell disorder, with or without an active leg ulcer.
Design:
- Participants will have a medical history and clinical evaluation. They will also have blood drawn.
- Participants will complete questionnaires about their life, health, environment, stress, and other topics.
- Participants may provide a small sample of hair.
- Participants will be asked to collect a small amount of saliva.
- Participants with leg ulcers will have their skin microbiome sampled. The microbiome is all of the microbes (bacteria and and/or fungi) and their genes in and on the body. Researchers will use swabs to collect skin samples. Photographs will be taken of the skin sample area.
- Some participants without leg ulcers also will have their skin microbiome sampled.
- Some participants who have their skin microbiome sampled will return for a second visit. At this visit, their microbiome will be resampled. It will take place more than 30 days after the first visit.
--Back to Top--
INCLUSION CRITERIA: We will enroll up to four-hundred and fifty (N=450) participants in the microbiome sampling cohort. In addition to the 300 SCD leg ulcer microbiome participants, we will recruit up to an additional 200-250 SCD participants that will complete the clinical evaluation, (including blood sample) and survey instruments for a total of up to 550 participants at three sites, NIH (n=200) and MMC (n=100), and Sierra Leone (n=250). Of the total participants, we will resample the microbiome of up to 75 individuals from each of the 3 initial sampling groups: SCD with, without and never had SCD leg ulcers. Of those 75 individuals who are sampled longitudinally, those with clinically interesting cases may be sampled at multiple intervals. All sampling, surveys, and processing of samples will take place at the NIH Clinical Center the second site, MMC, or in Sierra Leone. All samples will be stored at NIH. To be eligible to participate in this study, an individual must meet all of the following criteria: -- All subjects must have a diagnosis of sickle cell disease (HbSS, HgSC, HbSB 0 or HBSB+) -- Be at least 18 years old. -- Provide written informed consent. --For the Qualitative phase: must have a recurrent, active, or single-occurrence presentation of a leg ulcer(s). --For the resilience study analysis: cohort will be determined by the research team based on the results of part I of this analysis. For part I, the inclusion criteria are that the individual must have enrolled and completed the INSIGHTS study. EXCLUSION CRITERIA: Any individual that meets any of the following criteria during baseline evaluation will be excluded from the study: -- Pediatric population (<18 years old) -- Participants for microbiome study (only) who have received oral and/or topical antibiotics or antifungals < 2 weeks prior to enrolling in the study for leg ulcers (for those with leg ulcers only) -- Subjects presenting with clinically diagnosed bacterial infection (i.e. clinical appearance, clinical judgment, fever, redness around ulcer, purulent drainage etc.) at the site of ulceration. (This can only be diagnosed clinically by the research nurse during sampling and is only applicable to those with leg ulcers only).
We will enroll up to four-hundred and fifty (N=450) participants in the microbiome sampling cohort. In addition to the 300 SCD leg ulcer microbiome participants, we will recruit up to an additional 200-250 SCD participants that will complete the clinical evaluation, (including blood sample) and survey instruments for a total of up to 550 participants at three sites, NIH (n=200) and MMC (n=100), and Sierra Leone (n=250).
Of the total participants, we will resample the microbiome of up to 75 individuals from each of the 3 initial sampling groups: SCD with, without and never had SCD leg ulcers. Of those 75 individuals who are sampled longitudinally, those with clinically interesting cases may be sampled at multiple intervals.
All sampling, surveys, and processing of samples will take place at the NIH Clinical Center the second site, MMC, or in Sierra Leone. All samples will be stored at NIH.
To be eligible to participate in this study, an individual must meet all of the following criteria:
-- All subjects must have a diagnosis of sickle cell disease (HbSS, HgSC, HbSB 0 or HBSB+)
-- Be at least 18 years old.
-- Provide written informed consent.
--For the Qualitative phase: must have a recurrent, active, or single-occurrence presentation of a leg ulcer(s).
--For the resilience study analysis: cohort will be determined by the research team based on the results of part I of this analysis. For part I, the inclusion criteria are that the individual must have enrolled and completed the INSIGHTS study.
EXCLUSION CRITERIA:
Any individual that meets any of the following criteria during baseline evaluation will be excluded from the study:
-- Pediatric population (<18 years old)
-- Participants for microbiome study (only) who have received oral and/or topical antibiotics or antifungals < 2 weeks prior to enrolling in the study for leg ulcers (for those with leg ulcers only)
-- Subjects presenting with clinically diagnosed bacterial infection (i.e. clinical appearance, clinical judgment, fever, redness around ulcer, purulent drainage etc.) at the site of ulceration. (This can only be diagnosed clinically by the research nurse during sampling
and is only applicable to those with leg ulcers only).
Principal Investigator
Referral Contact
For more information: